Cavinton Comfort, 10 mg 30 pcs

An agent which improves cerebral blood circulation and cerebral metabolism. It inhibits phosphodiesterase activity, which promotes accumulation of CAMP in tissues. It has a vasodilatory effect mainly on cerebral vessels, which is due to direct myotropic spasmolytic action.

The systemic BP decreases slightly. It improves blood supply and microcirculation in the brain tissue, reduces platelet aggregation and normalizes the rheological properties of the blood. Improves hypoxia tolerance of the brain cells, promoting oxygen transport to the tissues by reducing the affinity of red blood cells to it, increasing absorption and metabolism of glucose. Increases the content of catecholamines in brain tissues.

Pharmacokinetics

In oral administration, it is rapidly absorbed from the gastrointestinal tract. C_max in plasma is reached after approximately 1 h. When parenteral administration, V_d is 5.3 l/kg. T_1/2 is about 5 h.

Indications

Cerebral circulation disorders (including stroke, vertebro-basilar insufficiency, brain trauma, atherosclerotic changes of cerebral vessels, vascular dementia, hypertensive and posttraumatic encephalopathy), intermittent cerebral vascular failure and spasm; partial occlusion of arteries, headache, dizziness (including labyrinthine origin).Headache, dizziness (including of labyrinthine origin), memory impairment, movement disorders, including Apraxia, aphasia, arteriolosclerotic and angiospastic changes of the retina and choroid, arterial and venous thrombosis of the eye vessels, degenerative changes of the macula, secondary glaucoma due to vascular occlusion; age-related, vascular or toxic (drug) hearing impairment, Meniere’s disease, cochleovestibular neuritis, tinnitus; vasovestibular manifestations of menopausal syndrome (in combination with hormone therapy).

Active ingredient

Composition

1 tablet contains

Active ingredients:

Vinpocetine – 10 mg.

Associates:

Mannitol – 75.6 mg,

Pregelatinized corn starch – 38 mg,

butyl methacrylate copolymer – 9 mg,

How to take, the dosage

Individually. For oral administration – 5-10 mg 3 times a day.

Interaction

When used concomitantly with warfarin, a slight decrease in the anticoagulant effect of warfarin has been reported.

Concomitant parenteral use of vinpocetine and heparin may increase the risk of bleeding.

Special Instructions

It is not recommended for patients with labile BP and low vascular tone.

Patients taking hypotensive drugs or drugs that increase the QT interval, as well as those with poor tolerance of Vinca minor alkaloids and those with hepatic impairment should use with caution.

Do not give by injection, intravenous or intravenous stream.

Do not use while working for drivers of vehicles and people whose profession requires high concentration.

By parenteral administration in patients with diabetes mellitus it is necessary to control the blood glucose content (the solution contains sorbitol). In the presence of prolonged QT interval syndrome or concomitant use of drugs that provoke prolongation of the QT interval, ECG monitoring is necessary.

In hemorrhagic stroke parenteral use of the drug is allowed only after disappearance of acute phenomena (in 5-7 days).

There are not enough observations on the use of the drug in pediatric practice.

Contraindications

Hypersensitivity, severe forms of CHD and arrhythmias, first days after cerebral hemorrhagic stroke, increased intracranial pressure; pregnancy, lactation.

Side effects

Nervous system and sense organs: dizziness, headache, insomnia, somnolence, weakness.

Cardiovascular system and blood (hematopoiesis, hemostasis): delayed intraventricular conduction; ST-segment depression and QT interval prolongation, hypotension, tachycardia, extrasystole, skin redness, thrombophlebitis in the injection site.

Gastrointestinal disorders: dry mouth, nausea, heartburn.

Skin disorders: sweating.

Others: allergic reactions.

Similarities